You are here

Article info

Article menu
XML
Coronary artery disease
Original research
Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

Authors

  • Robert Sykes British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Glasgow, UKWest of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK PubMed articlesGoogle scholar articles
  • Michael Briscoe Department of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK PubMed articlesGoogle scholar articles
  • Thomas Krysztofiak Department of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK PubMed articlesGoogle scholar articles
  • Oliver Peck West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UKDepartment of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK PubMed articlesGoogle scholar articles
  • Kenneth Mangion British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Glasgow, UKDepartment of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK PubMed articlesGoogle scholar articles
  • Colin Berry British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Glasgow, UKWest of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UKDepartment of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Colin Berry; colin.berry{at}glasgow.ac.uk
View Full Text

Citation

Sykes R, Briscoe M, Krysztofiak T, et al
Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
Open Heart 2021;8:e001633. doi: 10.1136/openhrt-2021-001633

Publication history

  • Received February 25, 2021
  • Accepted May 16, 2021
  • First published June 2, 2021.
Online issue publication 
June 02, 2021

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.